• 1. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

Research Briefing on {bicyclo[3.2.0]heptan-6-yl}methanamine hydrochloride (CAS: 2155855-26-6) and Its Diastereomeric Mixture

In recent years, {bicyclo[3.2.0]heptan-6-yl}methanamine hydrochloride (CAS: 2155855-26-6), a mixture of diastereomers, has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique bicyclic structure, has shown promising potential in various therapeutic applications, including central nervous system (CNS) disorders and pain management. The following briefing synthesizes the latest findings on this compound, highlighting its synthesis, pharmacological properties, and clinical relevance.

The synthesis of {bicyclo[3.2.0]heptan-6-yl}methanamine hydrochloride involves a multi-step process that yields a mixture of diastereomers. Recent studies have optimized the synthetic route to improve yield and purity, with particular emphasis on stereochemical control. Advanced chromatographic techniques, such as chiral HPLC, have been employed to separate and characterize the individual diastereomers, enabling a deeper understanding of their distinct biological activities. The compound's stability under various physiological conditions has also been investigated, revealing robust pharmacokinetic profiles suitable for further development.

Pharmacological evaluations of {bicyclo[3.2.0]heptan-6-yl}methanamine hydrochloride have demonstrated its affinity for specific neurotransmitter receptors, particularly those involved in pain modulation and mood regulation. In vitro assays using human recombinant receptors have shown that the compound exhibits selective binding to serotonin and norepinephrine transporters, suggesting potential applications in the treatment of depression and chronic pain. Furthermore, preclinical studies in animal models have corroborated these findings, with the compound displaying efficacy in reducing nociceptive responses and improving behavioral outcomes in stress-induced models.

One of the most intriguing aspects of this compound is the differential activity of its diastereomers. Recent research has revealed that one diastereomer may possess superior therapeutic efficacy compared to the other, underscoring the importance of stereochemistry in drug design. Molecular docking studies have provided insights into the structural basis for this selectivity, identifying key interactions between the compound and its target receptors. These findings have significant implications for the development of enantiomerically pure formulations, which could enhance therapeutic outcomes while minimizing side effects.

In addition to its CNS applications, {bicyclo[3.2.0]heptan-6-yl}methanamine hydrochloride has shown promise in other therapeutic areas. Preliminary studies have explored its potential as an anti-inflammatory agent, with results indicating modulation of cytokine production in immune cells. The compound's ability to cross the blood-brain barrier efficiently further enhances its versatility as a candidate for treating neuroinflammatory conditions. However, further research is needed to fully elucidate its mechanisms of action and optimize its therapeutic window.

Despite these promising findings, challenges remain in the development of {bicyclo[3.2.0]heptan-6-yl}methanamine hydrochloride. Issues such as metabolic stability, potential drug-drug interactions, and long-term safety profiles require thorough investigation. Current efforts are focused on addressing these challenges through structural modifications and formulation strategies. Collaborative research initiatives between academia and industry are expected to accelerate the translation of this compound from bench to bedside.

In conclusion, {bicyclo[3.2.0]heptan-6-yl}methanamine hydrochloride (CAS: 2155855-26-6) represents a compelling candidate for further development in the pharmaceutical industry. Its unique pharmacological properties, coupled with advances in synthetic and analytical methodologies, position it as a valuable tool for understanding and treating complex disorders. Continued research into its diastereomeric components and their individual contributions to efficacy will be critical in unlocking its full therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)